Product Description
Sotalol belongs to a group of medicines called beta blockers. It's used to treat atrial fibrillation and other conditions that cause an irregular heartbeat (arrhythmia). (Sourced from: https://www.nhs.uk/medicines/sotalol/)
Mechanisms of Action: ADRB Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: Arrhythmia, Sinus | Atrial Fibrillation | Atrial Flutter | Ventricular Fibrillation | Ventricular Flutter | Arrhythmia, Sinus | Atrial Fibrillation | Atrial Flutter | Ventricular Fibrillation | Ventricular Flutter
Known Adverse Events: Bradycardia | Dizziness | Headache | Dyspnea | Asthenia
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|